Coupling Aptamers to Short Interfering RNAs as Therapeutics

RNA-based approaches are among the most promising strategies aimed at developing safer and more effective therapeutics. RNA therapeutics include small non-coding miRNAs, small interfering RNA, RNA aptamers and more recently, small activating RNAs. However, major barriers exist to the use of RNAs as...

Full description

Bibliographic Details
Main Authors: Vittorio de Franciscis, Laura Cerchia, Carla Lucia Esposito, Simona Camorani, Silvia Catuogno
Format: Article
Language:English
Published: MDPI AG 2011-10-01
Series:Pharmaceuticals
Subjects:
Online Access:http://www.mdpi.com/1424-8247/4/11/1434/
id doaj-8a8efd7285474f2eb06612d120b413b1
record_format Article
spelling doaj-8a8efd7285474f2eb06612d120b413b12020-11-25T03:37:16ZengMDPI AGPharmaceuticals1424-82472011-10-014111434144910.3390/ph4111434Coupling Aptamers to Short Interfering RNAs as TherapeuticsVittorio de FranciscisLaura CerchiaCarla Lucia EspositoSimona CamoraniSilvia CatuognoRNA-based approaches are among the most promising strategies aimed at developing safer and more effective therapeutics. RNA therapeutics include small non-coding miRNAs, small interfering RNA, RNA aptamers and more recently, small activating RNAs. However, major barriers exist to the use of RNAs as therapeutics such as resistance to nucleases present in biological fluids, poor chemical stability, need of specific cell targeted delivery and easy entry into the cell. Such issues have been addressed by several recent reports that show the possibility of introducing chemical modifications in small RNAs to stabilize the molecular conformation and increase by several fold their integrity, while still preserving the functional activity. Further, several aptamers have been developed as excellent candidates for the specific recognition of cell surface targets. In the last few years, by taking advantage of recent advances in the small RNA field, molecular bioconjugates have been designed that permit specific targeting and may act as cargoes for cell internalization of small RNAs acting on gene expression that will be discussed in this review.http://www.mdpi.com/1424-8247/4/11/1434/aptamerintracellular deliverymicroRNAsmall interfering RNA
collection DOAJ
language English
format Article
sources DOAJ
author Vittorio de Franciscis
Laura Cerchia
Carla Lucia Esposito
Simona Camorani
Silvia Catuogno
spellingShingle Vittorio de Franciscis
Laura Cerchia
Carla Lucia Esposito
Simona Camorani
Silvia Catuogno
Coupling Aptamers to Short Interfering RNAs as Therapeutics
Pharmaceuticals
aptamer
intracellular delivery
microRNA
small interfering RNA
author_facet Vittorio de Franciscis
Laura Cerchia
Carla Lucia Esposito
Simona Camorani
Silvia Catuogno
author_sort Vittorio de Franciscis
title Coupling Aptamers to Short Interfering RNAs as Therapeutics
title_short Coupling Aptamers to Short Interfering RNAs as Therapeutics
title_full Coupling Aptamers to Short Interfering RNAs as Therapeutics
title_fullStr Coupling Aptamers to Short Interfering RNAs as Therapeutics
title_full_unstemmed Coupling Aptamers to Short Interfering RNAs as Therapeutics
title_sort coupling aptamers to short interfering rnas as therapeutics
publisher MDPI AG
series Pharmaceuticals
issn 1424-8247
publishDate 2011-10-01
description RNA-based approaches are among the most promising strategies aimed at developing safer and more effective therapeutics. RNA therapeutics include small non-coding miRNAs, small interfering RNA, RNA aptamers and more recently, small activating RNAs. However, major barriers exist to the use of RNAs as therapeutics such as resistance to nucleases present in biological fluids, poor chemical stability, need of specific cell targeted delivery and easy entry into the cell. Such issues have been addressed by several recent reports that show the possibility of introducing chemical modifications in small RNAs to stabilize the molecular conformation and increase by several fold their integrity, while still preserving the functional activity. Further, several aptamers have been developed as excellent candidates for the specific recognition of cell surface targets. In the last few years, by taking advantage of recent advances in the small RNA field, molecular bioconjugates have been designed that permit specific targeting and may act as cargoes for cell internalization of small RNAs acting on gene expression that will be discussed in this review.
topic aptamer
intracellular delivery
microRNA
small interfering RNA
url http://www.mdpi.com/1424-8247/4/11/1434/
work_keys_str_mv AT vittoriodefranciscis couplingaptamerstoshortinterferingrnasastherapeutics
AT lauracerchia couplingaptamerstoshortinterferingrnasastherapeutics
AT carlaluciaesposito couplingaptamerstoshortinterferingrnasastherapeutics
AT simonacamorani couplingaptamerstoshortinterferingrnasastherapeutics
AT silviacatuogno couplingaptamerstoshortinterferingrnasastherapeutics
_version_ 1724546119731511296